中国冶金工业医学杂志

PAI-1与2型糖尿病及其血管病变的关系

作者：何亚男赵晓娟

关键词：

分类号：R587.1

出版年,卷(期):页码：2008,25(4):0-0

摘要：

2型糖尿病(T2DM)大血管病变是患者致残和死亡的重要原因,而T2DM发生血管病变的机制复杂,目前研究表明,纤溶酶原激活物抑制剂-1(PAI-1)在T2DM及其血管病变的发生发展中起到关键作用[1,2].本文将PAI-1与T2DM及其血管病变关系的研究近况综述如下.

基金项目：

作者简介：

参考文献：

Losev R Z,Kuli kova AN.Modem views of diabetic angiopathy of the lower limbs (epidemiology,risk factor etiopathogenesis atherosclerosis of diabetes mellitus)Part Ⅰ[J].Angiol Sosud Khir,2005,11(3):14-20. Theuma P,Fonseca VA.Novel cardiovascular risk factors and macrovascular and microvascular complications of diabetes[J].Curr Drug Targets,2003,4(6):477-486. Festa A,D'Agostino R Jr,Tracy RP,et al.Elevated levels of acutephase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes:the insulin resistance atherosclerosis study.Diabetes,2002,51:1131-1137. He G,Bruun JM,Lihn AS,et al.Stimulation of PAl-1 and adipokines by glucose in human adipose tissue in vitro.Biochem Biophys Res Commun,2003,310:878-883. Juhan-Vague I,Alessi MC,Mavri A,et al.Plasminogen activator inhibitor-l,inflammation,obesity,insulin resistance and vascular risk J.J Thromb Haemost,2003,1(?):1575-1579. Eriksson P,Nillsson L,Karpe E,et al.Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired firinolysis of hypertriglyceridaemia[J].Arteriosler Thromb Vasc Biol,1998,18(1):20. Pandolfi A,Giaccari A,Cillic,et al.Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type-1 in the rat[J].Acts Diabetol,2001,38fll. Samad F,Pandey M,Bell PA,et al.Insulin continues to induce plasminogen activator inhibitor I gene expression in insulinresistant mice and adipocytes[J].Mol Med,2000,6:680. 赵世华,李长贵.血浆纤溶酶原激活物抑制物1与代谢综合征的相关性研究.中华内分泌代谢杂志,2005,21(4):318-319. 梁翠格,于桂娜.PAI-1与糖尿病肾病相关研究[J].山东医药,2005,45(70):68. Festa A,Agostino R,Tracy RP,et al.Elevated levels of acute phase proteins and plasminogen Activator inhibitor 1 predict the development of type 2 diabetes J.Diabetes,2002,51 (4):1131-1137. 张晓平,柳春.TNF-α、t-PA/PAI-1在2型糖尿病血管并发症中的意义.辽宁医学杂志,2006,20(1):13-14. Takazoe K,Ogawa H,Yasue H,et al.Increased plasminogen activator inhibitor activity and diabetes predict subsequent coronary events in patients with angina pectoris[J].Ann Med,2001,33 (3):206. Zhu Y,Farreh PM,Fay WP.Plasminogen activator inhibitor-1 enhances enhances neointima formation after oxidative vascular injury in atherosclerosis pronemice[J].Circulation,2001,103(25):3105. 赵玲,黄春林,卢富华.糖毒清对糖尿病肾病大鼠肾组织TGFβ1mRNA及PAl-1表达的影响.广东医学,2006,27(2):188-189. 刘亚军,严钟德,庞久高.纤溶酶原激活物抑制物-1与糖尿病肾病[J].中国糖尿病杂志,2002,10(6):373. He G,Pedersen SB,BruunJM,et al.Metformin,but not thiazoledin-edions,Inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro J.Horm Metab Res,2003,35(1):18-23. Nordt TK,Lutzi S,Ruef J,et al.Attenuation by fihrates of plasminogen activator inhibitor type-1 expression in human arterial smooth muscle cells J.Thromb Haemost,2001,86(5):1305-1313. Tsikouris JP,Suarez JA,Meyerrose GE.Plasminogen activator inhibitor-l:physiologic role,regulation,and the influence of common pharmacologic agents J.J Clin Pharmacoi,2002,42 (11):1187-1199. Pahor M,Franse LV,Deitcher SR,et al.Fosinopril versus amlodipine comparative treatments study:a randomized trial to assess effects on plasminogen activator inhibitor-1 J.Circulation,2002,105(4):457-461. Devaraj S,Chan AV Jr,Jialal L Alpha-Tocopherol supplementation decreases plas-minogen activator inhibitor 1 and P-selectin levels in type 2 diabetic patients[J].Diabetes Care,2002,25(3):524-529. Kawano H,Yasue H,Kitagawa A,et al.Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men[J].J Clin Endocrinol Metab,2003,88(7):3190-3195. Verbeke K,Oils A,Deelerck PJ.Inhibition of plasminogen activator inhibitor-1:antibody fragments and their unique sequences as a tool for the development of profibrinolytic drugs.J Thromb Haemost,2004,2,298-305. Elokdah H,Abou-Charbia M,Hennan JK,et al.Tiplaxtinin,a novel,orally efficacious inhibitor of plasminogen activator inhibitorl:design,synthesis,and preclinical characterization.J Med Chem,2004,47:3491-3494. Weisberg AD,Albornoz F,Griffin JP,et al.Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitorl attenuates angiotensin Ⅱ/salt-induced aortic remodeling.Arterioscler Thromb Vasc Biol,2005,25:365-371.

服务与反馈：

【文章下载】【加入收藏】